GLP1R and cancer: The results indicate a similar incidence of ORC between the study groups, despite the relative advantage of BMS in weight reduction, known to reduce cancer risk, with a direct effect of ∼40% risk reduction of GLP1-RAs compared to BMS beyond weight-loss.